Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENYCS FLY: Dapirolizumab pegol vs placebo in moderately to severely active SLE
jRCT2071220073Phase 3Recruiting
- Sponsor
- UCB
- Start
- Dec 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Dapirolizumab pegol arm with Placebo arm (2 arms). Primary endpoint: BICLA response at Week 48. Started Dec 2024; status: recruiting.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2071220073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220073.